Ibogaine vs. Ketamine — Key Differences for Practitioners

Mechanism of Action

Ketamine is primarily a dissociative anesthetic that works through NMDA receptor antagonism. Ibogaine is a multi-target compound that acts on serotonin transporters, NMDA receptors, opioid receptors, and promotes GDNF/BDNF neuroplasticity — a fundamentally different and more complex mechanism.

Duration

Ketamine sessions typically last 45–90 minutes. Ibogaine sessions last 24–36 hours. This difference in duration has enormous implications for clinical staffing, patient preparation, and the nature of the experience.

Safety Profile

Ketamine is FDA-approved (as Spravato for depression) and has a well-established safety profile. Ibogaine carries significant cardiac risks and requires comprehensive pre-treatment screening. Ketamine is safer for a broader patient population; ibogaine requires more careful patient selection.

Indications

Ketamine is primarily used for treatment-resistant depression and chronic pain. Ibogaine is primarily used for opioid addiction and PTSD — particularly in patients who have not responded to other treatments. The indications are largely complementary, not competitive.

Comparison Table: Ibogaine vs. Ketamine

Which Patients Are Best Suited for Each?

Ketamine is appropriate for a broader patient population — particularly those with treatment-resistant depression, anxiety, or chronic pain who have not responded to conventional treatments. Its FDA approval, established safety profile, and availability make it accessible to patients who cannot travel to Mexico or Costa Rica.

Ibogaine is most appropriate for patients with opioid use disorder, PTSD (particularly veterans), or who have not responded to other treatments including ketamine. Its more demanding experience and cardiac risks mean it requires more careful patient selection and preparation — but for the right patients, it can produce results that no other treatment achieves.

Can ibogaine and ketamine be combined?

Combining ibogaine and ketamine is not recommended and has not been studied. Both affect NMDA receptors, and the combination could have unpredictable effects. Patients should not use ketamine in the weeks before or after ibogaine treatment.

Is ibogaine more effective than ketamine for depression?

There is insufficient comparative evidence to make this claim. Ketamine has strong evidence for treatment-resistant depression. Ibogaine has shown promise for depression in some studies, but the evidence base is much smaller. For most depression patients, ketamine is the more appropriate choice given its safety profile and legal availability.

Can a practitioner offer both ibogaine integration and ketamine support?

Yes. Many practitioners work across multiple psychedelic modalities. Ibogaine integration coaching and ketamine-assisted therapy support are complementary skills. TII's certification focuses on ibogaine but provides a foundation that transfers to other psychedelic modalities.

Which has a better safety profile?

Ketamine has a significantly better safety profile for most patients. It is FDA-approved, has decades of clinical use, and does not carry the cardiac risks associated with ibogaine. Ibogaine's safety risks are manageable with proper screening and monitoring, but they require a higher level of clinical infrastructure.